drug
palivizumab
Marketedupdated 5mo agoby Sobi Inc
Approvedcommunity read0 votes
all catalysts(0)
nothing on the calendar yet
Trials studying palivizumab
- N/AStudy of Palivizumab in Children With High Risk of Severe Respiratory Syncytial Virus (RSV) Disease
- phase3Clesrovimab (MK-1654) in Infants and Children at Increased Risk for Severe Respiratory Syncytial Virus (RSV) Disease (MK-1654-007)
- phase1A PK Study Comparing MB05, EU-sourced Synagis® and US-sourced Synagis® in Healthy Volunteers.
- phase3A Study to Evaluate the Safety of MEDI8897 for the Prevention of Medically Attended Respiratory Syncytial Virus(RSV) Lower Respiratory Track Infection (LRTI) in High-risk Children
News(2)
- Chutes & Ladders—BioNTech brings in Sobi CEOAfter a six-month wait, BioNTech has finally filled its vacant CEO spot with Guido Oelkers, Ph.D. Oelkers hails from his tenure as CEO of Swedish pharma Sobi, where he oversaw the licensing of the…fiercebiotech · 1mo ago
- After 5-month wait, BioNTech announces Sobi CEO will take on top job at mRNA companyOne of the most closely watched vacancies in biopharma has now been filled, with Sobi CEO Guido Oelkers, Ph.D., moving across to take up the top job at mRNA pioneer BioNTech.fiercebiotech · 2mo ago
Data sources
last refreshed 2h ago
Found something off?
comments(0)
5-min edit window · permanent after that